Loading...
Last update:  May 26, 2023
08:28 +1GMT

Allergenic Molecule  Bet v 1Homo sapiens  
Epidemiology from Literature
CohortYearCountryTestSubjectsPositive (%)Bibliography
4.1.5 - Heterologous Source Sensitized (IgE)2009BelgiumBPT2065.00020091121, Ebo DG
5.2.1 - Source Exposed (Symptoms, SPT)2005GermanyHRT32100.00020050218, Erdmann SM
1.1 - Asymptomatic2014BelgiumIgE15100.00020140718, Faber MA
1.10 - Any allergy symptom, Diagnosed2010BelgiumIgE8633.72020101214, Gadisseur R
1.10 - Any allergy symptom, Diagnosed2010ItalyIgE164088.01020100301, Scala E
1.11 - Esophagitis, Diagnosed2013NetherlandsIgE7642.10020131020, van Rhijn BD
1.11 - Esophagitis, Diagnosed2013SwitzerlandIgE3534.28020130605, Simon D
1.12 - Oral Allergy Syndrome2014BelgiumIgE38100.00020140718, Faber MA
1.2.1 - Asthma, Diagnosed (Adults)2012SwedenIgE9647.92020120528, Patelis A
1.4 - Respiratory Symptoms, Diagnosed2012FranceIgE1298.50020121204, Caimmi D
1.4 - Respiratory Symptoms, Diagnosed2005GermanyIgE13232.60020050605, Mediaty A
1.4 - Respiratory Symptoms, Diagnosed2014ItalyIgE2123.80020141114, Costa C
1.4 - Respiratory Symptoms, Diagnosed2011SpainIgE684.40020110509, Rodriguez D
1.5 - Atopic Dermatitis, Diagnosed2014BelgiumIgE140.00020140718, Faber MA
1.5 - Atopic Dermatitis, Diagnosed2013GermanyIgE14031.43020130111, Ott H
1.5 - Atopic Dermatitis, Diagnosed2009GermanyIgE2055.00020091005, Ott H
1.5 - Atopic Dermatitis, Diagnosed2005GermanyIgE11323.90020050605, Mediaty A
1.5 - Atopic Dermatitis, Diagnosed2014Korea, Republic ofIgE254.00020140821, Choi JS
1.5 - Atopic Dermatitis, Diagnosed2014NetherlandsIgE21164.50020140331, Rockmann H
1.6 - Anaphylaxis, Diagnosed2014BelgiumIgE3732.43020140718, Faber MA
1.8 - Fruit Allergy2012SpainIgE21220.00020120912, Palacin A
1.9 - Pollen Allergy2014Czech RepublicIgE82654.20020140606, Panzner P
1.9 - Pollen Allergy2012SpainIgE11714.00020120912, Palacin A
10.1 - Normal Control2014BelgiumIgE150.00020140718, Faber MA
10.1 - Normal Control2012BelgiumIgE270.00020110223, De Knop KJ
10.1 - Normal Control2009BelgiumIgE260.00020091121, Ebo DG
3.1.1 - Source Sensitized (SPT)2003ItalyIgE40239.30020031005, Mari A
3.1.1 - Source Sensitized (SPT)2001ItalyIgE14557.1002001, Mari A
3.2.1 - Source Sensitized (IgE)2003AustriaIgE1095.0002003a, Westritschnig K
3.2.1 - Source Sensitized (IgE)2005FinlandIgE5585.00020041224, Moverare R
3.2.1 - Source Sensitized (IgE)2008JapanIgE5543.60020080319, Morita A
3.2.1 - Source Sensitized (IgE)1999NetherlandsIgE22363.2001999, Van Ree R
3.2.1 - Source Sensitized (IgE)2005Russian FederationIgE560.00020041224, Moverare R
3.2.1 - Source Sensitized (IgE)2010SwedenIgE10090.00020100212, Asarnoj A
3.2.1 - Source Sensitized (IgE)2003ZimbabweIgE30.0002003a, Westritschnig K
4.1.1 - Heterologous Source Sensitized (Symptoms)2013NetherlandsIgE8292.68020130415, Masthoff LJ
4.1.1 - Heterologous Source Sensitized (Symptoms)2013NetherlandsIgE7981.01020130415, Masthoff LJ
4.1.1 - Heterologous Source Sensitized (Symptoms)2005SwitzerlandIgE4097.50020050714, Ballmer-Weber BK
4.1.1 - Heterologous Source Sensitized (Symptoms)2004SwitzerlandIgE22100.00020040111, Mittag D
4.1.2 - Heterologous Source Sensitized (Symptoms, SPT)2003SpainIgE766.60020031017, Fernandez-Rivas M
4.1.2 - Heterologous Source Sensitized (Symptoms, SPT)2000SwitzerlandIgE2290.1002000, Luttkopf D
4.1.3 - Heterologous Source Sensitized (SPT)2013ItalyIgE1861.11020131031, Bonura A
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012AustriaIgE5433.30020120310, Twaroch TE
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2009BelgiumIgE2227.27020091121, Ebo DG
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2013ChinaIgE3850.00020130624, Ma S
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012DenmarkIgE3083.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012DenmarkIgE2085.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2002DenmarkIgE24100.0002002, Luttkopf D
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012ItalyIgE2626.90020120310, Twaroch TE
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012JapanIgE9370.97020120130, Fukutomi Y
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012JapanIgE21100.00020120130, Fukutomi Y
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012NetherlandsIgE4280.95020120905, Le TM
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012SpainIgE200.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012SpainIgE922.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2010SpainIgE506.50020101124, Vereda A
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2011SwedenIgE7479.73020110701, Moverare R
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2010SwedenIgE3582.90020101124, Vereda A
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012SwitzerlandIgE2195.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2012SwitzerlandIgE20100.00020120410, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2002SwitzerlandIgE19100.0002002, Luttkopf D
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2001SwitzerlandIgE20100.0002001, Ballmer-Weber BK
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2013ThailandIgE1915.80020131011, Suratannon N
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2010United StatesIgE3046.20020101124, Vereda A
4.1.5 - Heterologous Source Sensitized (IgE)2013ChinaIgE4924.50020130624, Ma S
4.1.5 - Heterologous Source Sensitized (IgE)2013ItalyIgE9635.41020131128, Calamelli E
4.1.5 - Heterologous Source Sensitized (IgE)2011ItalyIgE108473.61020110211, DAvino R
4.1.5 - Heterologous Source Sensitized (IgE)2013SloveniaIgE3735.14020131106, Homsak M
4.1.5 - Heterologous Source Sensitized (IgE)2010SwedenIgE500.00020100212, Asarnoj A
4.1.5 - Heterologous Source Sensitized (IgE)2013ThailandIgE210.00020131011, Suratannon N
4.1.6 - Heterologous Source Sensitized (High IgE)2011AustriaIgE6098.33020110211, DAvino R
4.1.6 - Heterologous Source Sensitized (High IgE)2011ItalyIgE214100.00020110211, DAvino R
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2013AustriaIgE20100.00020130401, Berneder M
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2013BelgiumIgE2180.95020130401, Ebo DG
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009DenmarkIgE2185.71020090406, Skamstrup Hansen K
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2007Denmark / Italy / SwitzerlandIgE3070.00020070323, Ballmer-Weber BK
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2011ItalyIgE14859.46020110810, Pastorello EA
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2011NetherlandsIgE2085.00020110304, Vissers YM
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2012SpainIgE2330.00020120726, Flores E
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2011SpainIgE854.20020110304, Garcia BE
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009SpainIgE2015.00020090406, Skamstrup Hansen K
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009SwitzerlandIgE2492.00020091005, Bauermeister K
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009SwitzerlandIgE2195.23020090406, Skamstrup Hansen K
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2000SwitzerlandIgE2290.9002000, Luttkopf D
5.2.1 - Source Exposed (Symptoms, SPT)1996FranceIgE5192.1001996, Pauli G
5.2.1 - Source Exposed (Symptoms, SPT)2005GermanyIgE32100.00020050218, Erdmann SM
5.3.1 - Source Exposed (Symptoms, IgE)2014AustriaIgE21788.00020141002, Deifl S
5.3.1 - Source Exposed (Symptoms, IgE)2014AustriaIgE35100.00020141020, Guhsl EE
5.3.1 - Source Exposed (Symptoms, IgE)2012BelgiumIgE9979.80020110223, De Knop KJ
5.3.1 - Source Exposed (Symptoms, IgE)2013ChinaIgE1687.50020130510, Ma S
5.3.1 - Source Exposed (Symptoms, IgE)2010Czech RepublicIgE17889.90020101026, Sekerkova A
5.3.1 - Source Exposed (Symptoms, IgE)2011GermanyIgE25892.63020110327, Canis M
5.3.1 - Source Exposed (Symptoms, IgE)2003ItalyIgE37257.80020030814, Rossi RE
5.3.1 - Source Exposed (Symptoms, IgE)2004Netherlands / SwitzerlandIgE20100.00020041204, Mittag D
5.3.1 - Source Exposed (Symptoms, IgE)2014SwedenIgE3768.00020140127, Konradsen JR
5.3.1 - Source Exposed (Symptoms, IgE)2014SwedenIgE2879.00020140127, Konradsen JR
5.3.1 - Source Exposed (Symptoms, IgE)2009SwitzerlandIgE2090.00020091005, Bauermeister K
5.3.1 - Source Exposed (Symptoms, IgE)2005SwitzerlandIgE21100.00020050714, Ballmer-Weber BK
5.3.2 - Source Exposed (Symptoms, high IgE)2001GermanyIgE8100.0002001, Foetisch K
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2011AustriaIgE22591.11020110121, Geroldinger-Simic M
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002AustriaIgE5098.0002002a, Moverare R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2009BelgiumIgE37100.00020090826, Ebo DG
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002FinlandIgE41100.0002002a, Moverare R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002FranceIgE5190.0002002a, Moverare R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2008GermanyIgE5092.00020081129, Treudler R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002ItalyIgE2162.0002002a, Moverare R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)1996ItalyIgE6569.2001996, Rossi RE
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2004PolandIgE1464.00020050112, Cudowska B
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002SwedenIgE4298.0002002a, Moverare R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2002SwitzerlandIgE3765.0002002a, Moverare R
5.4.2 - Source Exposed (Symptoms, SPT, high IgE)2003SwitzerlandIgE3497.10020030814, Tresch S
5.6.1 - Source Exposed (IgE)2009AustriaIgE9100.00020091216, Smole U
5.7.2 - Source Exposed (Provocation Test - Ingestion)2009DenmarkIgE20100.00020090406, Skamstrup Hansen K
5.7.2 - Source Exposed (Provocation Test - Ingestion)2009SpainIgE1717.65020090406, Skamstrup Hansen K
5.7.2 - Source Exposed (Provocation Test - Ingestion)2009SwitzerlandIgE20100.00020090406, Skamstrup Hansen K
6.2 - General Population (Adults)2012SwedenIgE37113.48020120528, Patelis A
6.3 - General Population (Children)2003SwedenIgE1955.60020030814, Kihlstrom A
6.3 - General Population (Children)2003SwedenIgE1797.30020030814, Kihlstrom A
6.3 - General Population (Children)2002SwedenIgE18516.8002002, Kihlstrom A
6.3 - General Population (Children)2002SwedenIgE18010.0002002, Kihlstrom A
6.3 - General Population (Children)2002SwedenIgE17014.7002002, Kihlstrom A
5.4.1 - Source Exposed (Symptoms, SPT, IgE)1989AustriaIgE (IB)5896.5001989b, Jarolim E
5.4.2 - Source Exposed (Symptoms, SPT, high IgE)1996SwitzerlandIgE (IB)5196.1001996, Menz G
5.4.2 - Source Exposed (Symptoms, SPT, high IgE)2003SwitzerlandNPT2391.30020030814, Tresch S
4.1.3 - Heterologous Source Sensitized (SPT)1999FranceSPT110.0001999a, Hoffmann-Sommergruber K
4.1.3 - Heterologous Source Sensitized (SPT)1999SwitzerlandSPT24100.0001999a, Hoffmann-Sommergruber K
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2000FranceSPT29100.0002000, Pauli G
5.4.2 - Source Exposed (Symptoms, SPT, high IgE)2003SwitzerlandSPT3491.20020030814, Tresch S
5.4.2 - Source Exposed (Symptoms, SPT, high IgE)1996SwitzerlandSPT51100.0001996, Menz G
Developed by
Panservice